(19)
(11) EP 4 798 248 A1

(12)

(43) Date of publication:
02.09.2026 Bulletin 2026/36

(21) Application number: 24837083.5

(22) Date of filing: 27.12.2024
(51) International Patent Classification (IPC): 
A61K 47/68(2017.01)
A61P 35/00(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 47/68037; A61K 47/6849; A61P 35/00; A61K 47/6803
(86) International application number:
PCT/EP2024/088555
(87) International publication number:
WO 2025/141153 (03.07.2025 Gazette 2025/27)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 29.12.2023 EP 23383412
22.07.2024 EP 24382795

(71) Applicant: Oncomatryx Biopharma, S.L.
48160 Derio (Vizcaya) (ES)

(72) Inventors:
  • EGAÑA GANUZA, Isabel
    Bizkaia (ES)
  • VARA, Yosu
    Bizkaia (ES)
  • ALDABA, Eneko
    Bizkaia (ES)
  • QUINTAS, Janire
    Bizkaia (ES)
  • FERRER, Cristina
    Bizkaia (ES)
  • SEIFERT, Oliver
    Bizkaia (ES)
  • KONTERMAN, Roland
    Bizkaia (ES)
  • FABRE, Myriam
    Bizkaia (ES)
  • SIMÓN BUELA, Laureano
    Bizkaia (ES)

(74) Representative: Mewburn Ellis LLP 
Aurora Building Counterslip
Bristol BS1 6BX
Bristol BS1 6BX (GB)

   


(54) ENDO180 TARGETED ANTIBODY-DRUG CONJUGATES